Inhibition of JNK signalling mediates PPARα‐dependent protection against intrahepatic cholestasis by fenofibrate

What is it about?

Treatment for cholestatic liver disease has been a great challenge for physicians because many patients do not respond to the classic medicine UDCA. Fenofibrate, a very safe and classic drug for dyslipidemia with a history of 5 decades, was reported to be beneficial for cholestasis. This work showed protective action by fenofibrate is dependent on PPARα, fenofibrate dose design, and inhibition of the JNK pathway.

Featured Image